sarsasapogenin has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Orsi, A; Rees, D; Xia, Z; Zhang, Y | 1 |
| Brotchie, JM; Callizot, N; Dixon, K; Howson, PA; Johnston, TH; Orsi, A; Rees, DD; Visanji, NP | 1 |
2 other study(ies) available for sarsasapogenin and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoprotection; Dopamine; Dopamine Agents; Female; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Mesencephalon; Neurons; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Spirostans; Tyrosine 3-Monooxygenase | 2008 |
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Disease Models, Animal; Glial Cell Line-Derived Neurotrophic Factor; Male; Mesencephalon; Mice; Nerve Growth Factors; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Spirostans; Tyrosine 3-Monooxygenase | 2008 |